Published in Vaccine Weekly, July 2nd, 2003
S. Dhalla announced the clinical trial at the 36th Annual Society of Epidemiological Research (SER) Meeting held in Atlanta, Georgia, June 11-14, 2003.
"The efficacy of a recombinant canarypox ALVAC-vCP205 HIV-1 vaccine will be studied in an initially seronegative group of IV drug users, a disadvantaged community of individuals. Excluded will be those with mental illness, history of malignancy or immunodeficiency, pregnancy, active tuberculosis, and recent receipt of blood products or a vaccine,"...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly